Metabolic peptides
The metabolic category covers the incretin family — peptides that activate one or more of the GLP-1, GIP, glucagon, and amylin receptors. The most-discussed compounds in 2026 research-peptide work fall into this group: the investigational triple agonist Retatrutide (Eli Lilly, currently in Phase 3) and the long-acting amylin analogue Cagrilintide (Novo Nordisk, in Phase 3 as the CagriSema combination).
Every metabolic SKU in the Omega Grade catalogue is supplied lyophilised in argon-purged amber glass (or in pre-filled research pen format), batch-tested by Janoshik Analytical (Slovakia), with a signed COA published on the product page before any lot lists for sale.
- SKUs in class
- 4
- Median purity
- ≥ 99%
- Verified by
- Janoshik · SVK
Retatrutide 40 mg pen
Triple-receptor agonist — pre-filled research pen, 4 × 10 mg.
- Form
- Pre-filled pen
- Dose
- 40 mg / 3 mL pen
- Purity
- ≥ 99.2%
Retatrutide 30 mg kit
Triple-receptor agonist — 30 mg vial, full research kit.
- Form
- Lyophilised kit
- Dose
- 30 mg / vial
- Purity
- ≥ 99.2%
Retatrutide 10 mg kit
Triple-receptor agonist — 10 mg vial, full research kit.
- Form
- Lyophilised kit
- Dose
- 10 mg / vial
- Purity
- ≥ 99.2%
Cagrilintide 10 mg
Long-acting amylin analogue — GLP-1 stack partner.
- Form
- Lyophilised kit
- Dose
- 10 mg / vial
- Purity
- ≥ 98.5%